The inverse agonist of CB1 receptor SR141716 blocks compulsive eating of palatable food.

Addict Biol

Laboratory of Addictive Disorders, Departments of Pharmacology and Psychiatry, Boston University School of Medicine, Boston, MA, USA.

Published: September 2014

Dieting and the increased availability of highly palatable food are considered major contributing factors to the large incidence of eating disorders and obesity. This study was aimed at investigating the role of the cannabinoid (CB) system in a novel animal model of compulsive eating, based on a rapid palatable diet cycling protocol. Male Wistar rats were fed either continuously a regular chow diet (Chow/Chow, control group) or intermittently a regular chow diet for 2 days and a palatable, high-sucrose diet for 1 day (Chow/Palatable). Chow/Palatable rats showed spontaneous and progressively increasing hypophagia and body weight loss when fed the regular chow diet, and excessive food intake and body weight gain when fed the palatable diet. Diet-cycled rats dramatically escalated the intake of the palatable diet during the first hour of renewed access (7.5-fold compared to controls), and after withdrawal, they showed compulsive eating and heightened risk-taking behavior. The inverse agonist of the CB1 receptor, SR141716 reduced the excessive intake of palatable food with higher potency and the body weight with greater efficacy in Chow/Palatable rats, compared to controls. Moreover, SR141716 reduced compulsive eating and risk-taking behavior in Chow/Palatable rats. Finally, consistent with the behavioral and pharmacological observations, withdrawal from the palatable diet decreased the gene expression of the enzyme fatty acid amide hydrolase in the ventromedial hypothalamus while increasing that of CB1 receptors in the dorsal striatum in Chow/Palatable rats, compared to controls. These findings will help understand the role of the CB system in compulsive eating.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3720761PMC
http://dx.doi.org/10.1111/adb.12056DOI Listing

Publication Analysis

Top Keywords

compulsive eating
20
palatable diet
16
chow/palatable rats
16
palatable food
12
regular chow
12
chow diet
12
body weight
12
compared controls
12
inverse agonist
8
agonist cb1
8

Similar Publications

Background: Substance use disorders (SUDs) represent a significant global public health challenge, with affected individuals often exhibiting poor dietary habits, nutritional deficiencies, and compromised mental and physical health. This scoping review evaluates existing literature on dietary intake in individuals with SUDs, focusing on the potential benefits of plant-based dietary interventions for improving nutritional status and supporting recovery.

Methods: A scoping review was conducted following PRISMA guidelines.

View Article and Find Full Text PDF

Association Between Cigarette Smoking and Subclinical Markers of Cardiovascular Harm.

J Am Coll Cardiol

March 2025

Ciccarone Center for Prevention of Cardiovascular Disease, Johns Hopkins Medicine, Baltimore, Maryland, USA; American Heart Association Tobacco Regulation and Addiction Center, Dallas, Texas, USA. Electronic address:

Background: Cigarette smoking is a strong risk factor for cardiovascular harm.

Objectives: The study sought to explore the detailed relationships between smoking intensity, pack-years, and time since cessation with inflammation, thrombosis, and subclinical atherosclerosis markers of cardiovascular harm.

Methods: We included 182,364 participants (mean age 58.

View Article and Find Full Text PDF

Purpose: Orthorexia Nervosa (ON) exhibits specific features that may overlap with Obsessive-Compulsive Disorder (OCD), Perfectionism Striving (PS), and Perfectionism Concern (PC). While previous literature has shown predictiveness in different characteristics of ON, this study aimed to determine if PS, PC and OCD symptoms could predict ON dimensions in at-risk populations using Bayesian models.

Method: The study enrolled 622 individuals from three different at-risk populations: people who were following treatment for an Eating Disorder (Patients), people who were following a diet (Dieters) and University students with a degree in medicine or nursing (Students).

View Article and Find Full Text PDF

Oral Health Risks of Transmucosal Buprenorphine: Commentary on Tuan et al. and Zheng et al.

J Addict Med

March 2025

Yale School of Medicine, New Haven, CT (ACB, WCB); Yale Program in Addiction Medicine, New Haven, CT (ACB, WCB); and VA Connecticut Healthcare System, West Haven, CT (ACB, WCB).

Opioid use disorder affects millions of people nationally and in 2022 opioid overdose deaths exceeded 80,000. Buprenorphine, a partial mu-opioid receptor agonist, is a gold standard treatment for opioid use disorder, improving withdrawal symptoms and decreasing opioid-related mortality. However, a 2022 Food and Drug Administration warning about oral health problems related to transmucosal formulations has precipitated new research into this medication's potential risks.

View Article and Find Full Text PDF

Amylin, also known as islet amyloid polypeptide (IAPP), is a pancreatic βcell peptide hormone involved in satiation and control food intake. It is also produced in smaller quantities by neurons, the gastrointestinal tract, and spinal ganglia. Numerous studies have revealed that patients with type 2 diabetes mellitus (T2DM) and cognitive deficits exhibit IAPP deposits in the pancreas, brain, and blood vessels.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!